This site is intended for U.S. healthcare professionals only

This site is intended for U.S. healthcare professionals only


Current treatment does not address the underlying cause of achondroplasia and is limited to management of complications. However, many different approaches to addressing excessive FGFR3 activity have been proposed and are under clinical trial investigation.1-3 None of these approaches has been determined to be safe or effective or approved for use.

Ongoing research into impaired endochondral bone growth4

Hover over each area for more information

impaired endochondral bone growth diagram
Chemical inhibitors to reduce FGFR3 tyrosine kinase activity
Antibodies to block receptor activation
Exogenous CNP to enhance CNP-mediated antagonism of downstream signals
RNAi to reduce FGFR3 production
Hsp90 inhibitors to induce degradation of activated receptor
Agents to disrupt direct nuclear signaling of FGFR3

References: 1. Högler W, Ward LM. New developments in the management of achondroplasia. Wien Med Wochenschr. 2020;170(5-6):104-111. 2. Ireland PJ, Pacey V, Zankl A, Edwards P, Johnston LM, Savarirayan R. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117-125. Published online June 24, 2014. 3. Wright MJ, Irving MD. Clinical management of achondroplasia. Arch Dis Child. 2012;97(2):129-134. 4. Laederich MB, Horton WA. Achondroplasia: pathogenesis and implications for future treatment. Curr Opin Pediatr. 2010;22(4):516-523.